載入中
NASDAQHealthcareMedical - Devices
最新資料
US$1.53
−US$0.04 · -2.55%
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
前收盤價
US$1.53
−US$0.04 · -2.55%
盤中時間採用ET。市場資料可能有所延遲。
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
日內區間
目前US$1.53
52週區間
目前US$1.53
盤中時間採用ET。市場資料可能有所延遲。
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
日內區間
目前US$1.53
52週區間
目前US$1.53
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 421.52萬 USD | 305.25萬 USD | 311.18萬 USD | 125.69萬 USD | — |
| 銷貨成本 | 216.52萬 USD | 180.57萬 USD | 168.62萬 USD | 93.02萬 USD | — |
| 毛利 | 205萬 USD | 124.69萬 USD | 142.56萬 USD | 32.67萬 USD | — |
| 研究與開發 | 337.13萬 USD | 239.65萬 USD | 167.38萬 USD | 50.74萬 USD | 385.39萬 USD |
| 銷售、一般及管理費用 | 1050.22萬 USD | 888.39萬 USD | 925.85萬 USD | 802.67萬 USD | 492.01萬 USD |
| 營業費用 | 1465.81萬 USD | 1189.15萬 USD | 1170.88萬 USD | 1292.19萬 USD | 833.69萬 USD |
| 利息收入 | 11.03萬 USD | 10.15萬 USD | 8.48萬 USD | 9676 USD | 1.44萬 USD |
| 利息支出 | 1.07萬 USD | 6.09萬 USD | 16.71萬 USD | 22.35萬 USD | 7539 USD |
| 折舊和攤銷 | 116.38萬 USD | 121.37萬 USD | 121.31萬 USD | 96.67萬 USD | — |
| 營業利益 | −1260.81萬 USD | −1064.46萬 USD | −1028.32萬 USD | −1259.52萬 USD | −833.69萬 USD |
| 淨利 | −1243.1萬 USD | −1056.87萬 USD | −1015.68萬 USD | −1063.17萬 USD | −830.61萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年12月16日 | 1:10 | — | — |
股票分割 | 2024年1月29日 | 1:12 | — | — |
股票分割 | 2023年2月10日 | 1:20 | — | — |
股票分割 | 2017年4月10日 | 2,000:1 | — | — |
股票分割 | 2016年12月28日 | 300:1 | — | — |
股票分割 | 2016年9月16日 | 80:1 | — | — |
已生效 2025年12月16日
1:10
已生效 2024年1月29日
1:12
已生效 2023年2月10日
1:20
已生效 2017年4月10日
2,000:1
已生效 2016年12月28日
300:1
已生效 2016年9月16日
80:1
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
